title: Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol.
abstract: In this double-blind study of changes in plasma lipid and lipoprotein concentrations during 6-month medical treatment of endometriosis, 53 patients were randomly assigned to one of four treatment schedules: danazol, 800 mg/day (n = 10); danazol, 600 mg/day (n = 8); intranasal nafarelin acetate, 800 micrograms/day (n = 10); or intranasal nafarelin acetate, 400 micrograms/day (n = 25). Plasma levels of triglycerides, cholesterol, and low-density lipoprotein, very low-density lipoprotein, and high-density lipoprotein cholesterol fractions were obtained before, during, and 1 month after treatment. High-density lipoprotein2 and high-density lipoprotein3 cholesterol concentrations were measured in selected patients. Body weight was also followed. The drugs were equally effective in achieving symptomatic relief and laparoscopically demonstrated resolution of endometriosis but differed significantly in their effects on lipid concentrations. Nafarelin acetate had no adverse effects on serum lipoprotein concentrations, whereas danazol significantly decreased high-density lipoprotein cholesterol (p less than 0.01), as well as the high-density lipoprotein2 subfraction (p less than 0.05), and increased low-density lipoprotein cholesterol (p less than 0.01). Danazol significantly increased body weight (p less than 0.01), whereas nafarelin did not.
authors.affiliation: Department of Obstetrics and Gynecology, Oregon Health Sciences University, School of Medicine, Portland 97201.
authors.forename: K A
authors.initials: KA
authors.lastname: Burry
authors.forename: P E
authors.initials: PE
authors.lastname: Patton
authors.forename: D R
authors.initials: DR
authors.lastname: Illingworth
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007247:Infertility, Female / Q000209:etiology; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D017274:Nafarelin; D011245:Pregnadienes / Q000627:therapeutic use*; D011247:Pregnancy; D011897:Random Allocation; D013997:Time Factors
chemical_list: D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011245:Pregnadienes; D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D002784:Cholesterol; D003613:Danazol